Document is current
Any future updates will be listed below
-
Authors
Schmidt, Michael J.
Naghdloo, Amin
Prabakar, Rishvanth K.
Kamal, Mohamed https://orcid.org/0000-0001-8663-8846
Cadaneanu, Radu
Garraway, Isla P.
Lewis, Michael
Aparicio, Ana
Zurita-Saavedra, Amado https://orcid.org/0000-0002-3805-7307
Corn, Paul
Kuhn, Peter
Pienta, Kenneth J. https://orcid.org/0000-0002-4138-2186
Amend, Sarah R.
Hicks, James
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01CA093900, P01CA093900, U54CA210173, U01CA196390, P50CA058236)
Epic Sciences
U.S. Department of Defense (W81XWH-20-10353, W81XWH-22–1-0680)
The Patrick C. Walsh Prostate Cancer Research Fund and the Prostate Cancer Foundation
- License Information
-
More Information
Article History
Received: 15 August 2024
Revised: 24 October 2024
Accepted: 28 October 2024
First Online: 22 November 2024
Competing interests
: The HDSCA technology described here is licensed to Epic Sciences. PK has ownership in Epic Sciences. JH discloses he is a member of the Clinical Advisory Board of Epic Sciences. KJP is a consultant for CUE Biopharma, Inc., and holds equity interest in CUE Biopharma, Inc., Keystone Biopharma, Inc., PEEL Therapeutics, Inc and Kreftect, Inc. SRA holds equity interest in Keystone Biopharma, Inc.
: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the University of Southern California Keck School of Medicine, MD Anderson (NCT01505868), and the VA of Los Angeles (PCC 2015-090980). Informed consent was obtained from all subjects involved in the study.
: All the authors agree to publish this paper.
